Tel Aviv University researcher goes 'through the nose' to delay onset of Alzheimer's disease

August 17, 2007

Tel Aviv -- Scientists working on a cure for Alzheimer's disease find it hard to develop drugs that will pass through the highly selective blood-brain barrier. That may be why a Tel Aviv University researcher decided to take an alternate route -- through the nose.

Scientists widely agree that plaque formation is what causes the onslaught of neurological diseases like Alzheimer's and other neurological disorders, such as amyotrophic lateral sclerosis (ALS). Administering a harmless bacterial virus known as a "filamentous phage" through nasal passages, Prof. Beka Solomon of the university's Molecular Microbiology and Biotechnology Department sends her phages to the brain where they lock onto plaques associated with Alzheimer's.

"Phages dissolve plaque," Prof. Solomon explains. "The phages are going into the brain, they do their work, and then the body gets rid of them." She recently presented her findings in Canada at a meeting of the American Society for Microbiology.

Alzheimer's is a debilitating disease that leads to memory loss, confusion, and much suffering for the afflicted and their loved ones. There is currently no drug on the market that can cure or effectively stop progression of the disease. Drug developers, says Prof. Solomon, "tend to focus on dissolving and preventing plaque formation, but the new approach prevents the unwanted side-effects shown by other therapies."

The idea of sending a treatment through the nasal passage was a logical one for Prof. Solomon, since Alzheimer's plaques first appear in the olfactory bulb. That's why one of the early symptoms of the much-dreaded disease is loss of smell. To test her hypothesis, Prof. Solomon treated mice with the phage, and found that those mice which had exhibited Alzheimer's symptoms regained their sense of smell and demonstrated memory improvement. After one year of treatment, they had 80 percent fewer plaques than untreated mice.

"Beka is a real pioneer in developing an immunotherapeutic approach for the treatment of Alzheimer's disease," says Irit Ben-Chlouch, Director of Business Development, Life Sciences at Ramot, the university's commercial arm. "She was the first to show the disease can be treated using antibodies and, as the main focus of her lab, has developed several different breakthrough approaches." Ben-Chelouche is commercializing the technology through Ramot on behalf of Tel Aviv University.
Ramot is the technology transfer company of Tel Aviv University. Ramot fosters, initiates, leads, and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading-edge science and innovation, offering new business opportunities in a broad range of emerging markets.

American Friends of Tel Aviv University supports Israel's leading center of higher learning, the largest Jewish university anywhere. It is ranked among the world's top 100 universities in science, biomedical studies, and social science, and rated one of the world's top 200 universities overall. Internationally recognized for the scope and groundbreaking nature of its research programs, Tel Aviv University consistently produces work with profound implications for the future.

American Friends of Tel Aviv University

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to